Why TE Connectivity’s Stock Is Shooting Higher Today?

TE Connectivity Ltd (NYSE: TEL) reported Q1 FY24 net sales of $3.83B, beating consensus and up 4% YoY. Adjusted EPS of $1.84 also beat consensus. CEO cites innovation and global position for growth in transportation and industrial segments. Q2 outlook falls below consensus.

TE Connectivity Ltd (NYSE:TEL) reported a first-quarter FY24 net sales of $3.83 billion, beating the consensus of $3.86 billion, essentially flat year-on-year. 

The net sales declined by 1% organically. The adjusted EPS of $1.84 beat the consensus of $1.71. 

Orders were $3.8 billion, up 4% year-over-year, with growth in all segments.

Revenue from Transportation Solutions rose by 5% Y/Y to $2.37 billion, Industrial Solutions decreased by 3.3% Y/Y to $1.03 billion, and Communications Solutions declined by 17% Y/Y to $433 million.

Margin: The adjusted operating margin improved by 290 bps to 19.1%.

TE Connectivity generated $570 million in free cash flow and held $1.17 billion in cash and equivalents.

TE Connectivity CEO Terrence Curtin acknowledged the company’s innovations and global position in automotive connectivity, including a strong presence in Asia, enabling it to deliver year-over-year growth in its Transportation segment. 

The industrial segment continued to benefit from growth in renewable energy, commercial air, and medical applications. The Communications segment delivered margins in the high teens, and the company expects revenue growth in artificial intelligence applications. 

Curtin expects strong margin performance at the company level throughout fiscal year 2024.

Outlook: TEL sees second-quarter net sales of $3.95 billion, vs. the consensus of $3.995 billion, and adjusted EPS of $1.82, vs the consensus of $1.78.

Price Action: TEL shares are trading higher by 7.40% at $144.62 on the last check Wednesday.

Total
0
Shares
Related Posts
Read More

Watching Bausch Health Companies; Seeking Alpha Reports, Court Ruling In Patent Dispute With Norwich Pharma; Court Issued An Order Denying Norwich’s Motion To Modify Judgment In The Case Of: “Salix Pharmaceuticals, Ltd. Norwich Pharmaceuticals, Inc.”

https://seekingalpha.com/news/3972676-bausch-health-soars-after-court-ruling-in-patent-dispute-with-norwich-pharma?utm_campaign=twitter_automated&utm_content=news&utm_medium=social&utm_source=twitter_automated Bausch Health (NYSE:BHC) soared 40% after a court ruling related to the company’s patent suit vs Norwich Pharma over…

BHC